22 October 2026 RLS-2202 PHASE 1A TRIAL ADVANCES TO COHORT 2 HIGHLIGHTS • Safety Review Committee has completed its review of Cohort 1 safety and pharmacokinetic data and determined the dose for Cohort 2 progression. • Recruitment for Cohort 2 is expected to commence shortly. • Patrys remains...